Strep A Vaccine Global Consortium (SAVAC)

Gold Sponsor

Strep A Vaccine Global Consortium (SAVAC) Group A Streptococcus (GAS), Streptococcus pyogenes, is the biggest infectious killer that no one has heard of. The concerning global disease causes an estimated 18 million people to suffer, and 517,000 deaths with 1.8 million new cases annually. A great proportion of the disease lies in low- and middle-income countries. The greatest burden is due to rheumatic heart disease, but invasive GAS diseases also contribute significantly. GAS pharyngitis is a major driver of inappropriate, global antibiotic use. There is a significant global need to reinforce current control strategies and develop new primary prevention strategies including vaccines. On 31 May 2017, the Executive Board of the World Health Organization (WHO) proposed a Resolution on ‘Rheumatic Fever and Rheumatic Heart Disease' adopted at the Seventy-first World Health Assembly in May 2018. Although a number of vaccine candidates have been developed, there has been little financial investment beyond early-stage clinical studies, and no major manufacturer has a GAS vaccine program. In line with its mission, Strep A Vaccine Global Consortium (SAVAC) was formed to develop a full value of vaccines analysis for a Strep A vaccine, provide insight into potential safety risks, better define the burden of disease, and explore correlates of protection. With the successful completion of SAVAC, SAVAC 2.0 follows to facilitate the development of Step A vaccines by (1) preparing for future clinical trials, (2) preparing industry stakeholder, and (3) preparing non-industry stakeholders for a future Strep A vaccine(s). SAVAC 2.0 is expected to revise and enable the R&D roadmap, refine the public health value proposition with WHO, and further critical discussions around endpoints, safety, correlates, and disease pathogenesis (as it relates to vaccines). From development to delivery, the SAVAC will be a steppingstone on the way to an endless horizon of a safe, globally effective, and affordable GAS vaccine